(Cervical Cancer) Is Cemiplimab Effective? EMPOWER-Cervical 1 Phase 3 Trial Results
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- June 7, 2021
- 2 min read
The EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 Phase 3 clinical trial evaluated cemiplimab (anti-PD-1 antibody) versus investigator's choice of chemotherapy in patients with recurrent cervical cancer who had progressed on prior platinum-based therapy. Results were published in the New England Journal of Medicine.
Trial Design:
Patients with recurrent, metastatic, or persistent cervical cancer who had progressed on prior platinum-containing chemotherapy were randomized to receive either cemiplimab 350 mg IV every 3 weeks or investigator's choice of single-agent chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary endpoint was overall survival (OS).
Results:
- Median OS: Cemiplimab 12.0 months vs. chemotherapy 8.5 months
- Hazard ratio: 0.69 (31% reduction in death risk)
- The OS benefit was observed regardless of PD-L1 expression status
Conclusion: Based on the EMPOWER-Cervical 1 trial results, cemiplimab demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy in patients with recurrent cervical cancer following platinum-based therapy.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.
Source: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9. N Engl J Med. 2021.
Cervical Cancer | Immunotherapy | Cemiplimab
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4